Metformin for Multiple Sclerosis
Trial Summary
What is the purpose of this trial?
This trial tests the feasibility of starting metformin at different times. Participants will take metformin for several months. Metformin helps lower blood sugar levels by reducing sugar release from the liver and improving insulin response. The likely target group is people with type 2 diabetes. Metformin has been shown to be effective in improving glycemic control in type 2 diabetes and has a history of being used in various dosages and combinations to manage blood sugar levels.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are on insulin, certain drugs that interact with metformin, or other remyelinating therapies. Your current medications will be reviewed by the trial investigators to ensure they don't interfere with metformin.
Is metformin safe for use in humans?
Metformin, commonly used for diabetes, has been studied for safety in various conditions, including as an additional treatment for multiple sclerosis. It is generally considered safe for human use, but like any medication, it may have side effects, so it's important to discuss with a healthcare provider.12345
How is the drug Metformin unique in treating multiple sclerosis?
Metformin is unique in treating multiple sclerosis because it is traditionally used for managing type 2 diabetes by improving insulin sensitivity, which is different from typical MS treatments like glatiramer acetate that focus on modulating the immune system. This novel approach suggests a potential new mechanism of action for MS treatment.56789
Research Team
E. Ann Yeh, MA, MD, FRCPC, Dip ABPN
Principal Investigator
The Hospital for Sick Children
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive metformin or placebo for a minimum of 3 months and a maximum of 9 months, depending on randomization
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Metformin
- Placebo
Metformin is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Hospital for Sick Children
Lead Sponsor
Ontario Institute for Regenerative Medicine
Collaborator
Unity Health Toronto
Collaborator
Stem Cell Network
Collaborator
Multiple Sclerosis Society of Canada
Collaborator
Queen's University
Collaborator
Kingston Health Sciences Centre
Collaborator
Queen's University
Collaborator